Study #2020-1258
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at lea
MD Anderson Study Status
Not Accepting
Treatment Agent
Axatilimab
Description
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Chronic Graft-versus-host-disease
Study phase:
Phase II
Physician name:
Rohtesh Mehta
Department:
Stem Cell Transplantation
For general questions about clinical trials:
1-855-757-2402
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.